Abstract: Objective This study was conducted to investigate efficacy of pegylated interferon α-2a (peg-IFNα-2a) and albavir/granrivir combination in the treatment of patients with chronic hepatitis C (CHC). Methods 74 patients with CHC were encountered in our hospital between January 2018 and January 2022, and we assigned them to receive peg-IFNα-2a and albavir/granrivir combination therapy (observation, n=37) for 12 weeks, or to receive peg-IFNα-2a and ribavirin combination therapy (control, n=37) for 24 weeks. Serum HCV RNA loads and other laboratory tests were recorded. Results Rapid virological response rate, end of treatment virological response rate and sustained virological response rate in observation group were 70.3%, 97.3% and 94.6%, all significantly higher than 37.8%, 62.2% and 54.1% in the control (P<0.05); by week 4, week 12 and week 24 of follow-up, serum HCV RNA loads in the observation were (1.6±0.8)lg u/ml, (1.5±0.9)lg u/ml and (1.2±0.3)lg u/ml, all significantly lower than [(4.3±0.9)lg u/ml, (4.5±0.8)lg u/ml and (3.2±0.5)lg u/ml, respectively, P<0.05] in the control; by end of antiviral treatment, peripheral blood WBC, RBC, PLT counts and Hb concentration in the observation were (5.1±1.0)×10⁹/L, (4.9±0.6)×10¹²/L, (101.8±17.5)×10⁹/L and (120.5±19.5)g/L, all significantly higher than [(3.3±0.9)×10⁹/L, (4.3±0.5)×10¹²/L, (85.8±17.3)×10⁹/L and (100.3±16.3)g/L, respectively, P<0.05] in the control, and serum ALT and AST levels were (34.6±5.8)U/L and (36.4±6.9)U/L, both much lower than [(46.3±6.9)U/L and (49.1±7.5)U/L, respectively, P<0.05] in the control group. Conclusion Combination of peg-IFN α-2a and albavir/graniclovir in treatment of patients with CHC could obtain a satisfactory antiviral efficacy, improve liver function recovery.

Key words: Hepatitis C, Albavir, Granrivir, Pegylated interferon α-2a, Therapy